# Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma

> **NCT03466450** · PHASE1,PHASE2 · COMPLETED · sponsor: **Grupo Español de Investigación en Neurooncología** · enrollment: 75 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** PF-04449913
- **DRUG:** Temozolomide Oral Capsule

## Key facts

- **NCT ID:** NCT03466450
- **Lead sponsor:** Grupo Español de Investigación en Neurooncología
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-15
- **Primary completion:** 2023-11-29
- **Final completion:** 2023-11-29
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2024-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03466450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03466450, "Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03466450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*